Scancell Holdings Plc Scancell strengthens IP portfolio (3709T)
20 March 2019 - 6:01PM
UK Regulatory
TIDMSCLP
RNS Number : 3709T
Scancell Holdings Plc
20 March 2019
20 March 2019
Scancell Holdings Plc
("Scancell" or the "Company")
Scancell strengthens IP portfolio for immunotherapy
platforms
Grant of US patent that protects Modi-1, the first clinical
candidate from its Moditope(R) immunotherapy platform
Additional grant of European patent for anti-glycan antibody
Scancell Holdings plc, the developer of novel immunotherapies
for the treatment of cancer, today announces that the United States
Patent Office has granted a US patent that provides protection for
Modi-1, the first clinical candidate from Scancell's Moditope(R)
immunotherapy platform.
US patent number 10,233,220, entitled Anti-tumour Response to
Modified Self-epitopes was granted on 19 March 2019 and claims
methods of stimulating an immune response to a tumour and methods
of treating cancer using peptides of Modi-1. Additional claims that
aim to protect other aspects of the Moditope(R) platform are being
pursued in the US. Grant in the US follows grant of corresponding
patents in Europe, as announced last year, South Africa and
Australia, and acceptance for grant in China. Counterparts to these
patents are being prosecuted in other territories of importance to
Scancell.
The Company also today announces the grant of European patent
number 3,063,160 relating to FG88 a monoclonal antibody directed to
tumour associated glycans, further strengthening the commercial
positioning of Scancell's monoclonal antibody development
programme.
Dr Cliff Holloway, Chief Executive Officer, Scancell, said:
"We are pleased to have been granted these two important patents
for our immunotherapy platforms in the United States and Europe.
This Moditope(R) patent provides protection for Modi-1 in the US
and further endorses the novelty of Scancell's work in identifying
a new class of cancer vaccine. Through the continued expansion of
our intellectual property portfolio in the US and Europe, we
believe we are well positioned to advance our pipeline of novel
immunotherapies."
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014 (MAR).
For Further Information:
Scancell Holdings Plc
Dr John Chiplin, Chairman +44 (0) 20 3727 1000
Dr Cliff Holloway, CEO
Panmure Gordon (UK) Limited
(Nominated Adviser and Corporate
broker)
Freddy Crossley/Emma Earl +44 (0) 20 7886 2500
FTI Consulting
Simon Conway/Natalie Garland-Collins +44 (0) 20 3727 1000
About Scancell
Scancell is developing novel immunotherapies for the treatment
of cancer based on its ImmunoBody(R) and Moditope(R) technology
platforms.
ImmunoBody(R) vaccines target dendritic cells and stimulate both
parts of the cellular immune system. They can be used as
monotherapy or in combination with checkpoint inhibitors. This
platform has the potential to enhance tumour destruction, prevent
disease recurrence and extend survival.
-- SCIB1, the lead programme, is being developed for the
treatment of melanoma. A phase 1/2 clinical trial has so far
successfully demonstrated survival data of more than five
years.
-- SCIB2 is being developed for the treatment of non-small cell
lung cancer and other solid tumours. Scancell has entered into a
clinical development partnership with Cancer Research UK for
SCIB2.
Moditope(R) represents a completely new class of potent and
selective immunotherapy agents based on stress-induced
post-translational modifications (siPTM). It stimulates the
production of killer CD4+ T cells which overcome the immune
suppression induced by tumours, allowing activated T cells to seek
out and kill tumour cells that would otherwise be hidden from the
immune system. Moditope(R) alone, or in combination with other
agents, has the potential to treat a wide variety of cancers.
-- Modi-1 is being developed for the treatment of solid tumours
including triple negative breast cancer, ovarian cancer and head
and neck cancer.
For further details, please see our website:
www.scancell.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCDDGDXRXBBGCC
(END) Dow Jones Newswires
March 20, 2019 03:01 ET (07:01 GMT)
Scancell (LSE:SCLP)
Historical Stock Chart
From Apr 2024 to May 2024
Scancell (LSE:SCLP)
Historical Stock Chart
From May 2023 to May 2024